Oxidant/Antioxidant Status in Patients with BCR-ABL1 Negative Myeloproliferative Neoplasms

Excessive production of reactive oxygen species (ROS) leading to oxidative stress have been associated with many leukemias. In order to show whether there is a difference in ROS levels and total antioxidant power between BCR-ABL1 negative myeloproliferative neoplasms (MPNs) patients and controls, this study aims to evaluate the oxidant/antioxidant status in patients with MPN. 43 subjects with BCR-ABL1 negative MPNs and 40 healthy controls were included in this study. Oxidative stress was investigated by determination of total antioxidant power, catalase activity and concentrations of vitamins (A, C and E), malondialdehyde, hydroperoxides and carbonylated proteins. Oxygen Radical Absorbance Capacity (ORAC) was lower in BCR-ABL1 negative MPN patients compared with control group (0.40 +/- 0.17 vs. 0.81 +/- 0.06) AU (p<0.01). Vitamins A (0.61 +/- 0.19 vs. 0.82 +/- 0.11) mol/L (p<0.05), E (0.29 +/- 0.08 vs. 1.10 +/- 0.56) mol/L (p<0.01) and C (19.22 +/- 0,49 vs. 45.52 +/- 0.36)mu g/mL (p<0.01) concentrations were lower in the same group compared to controls. No difference in catalase (CAT) activity between the BCR-ABL1 negative MPN and control groups was observed (p > 0.05). Higher malondialdehyde (MDA) plasma levels were found in BCR-ABL1 negative MPN patients compared to controls (2.97 +/- 0.24 vs. 0.38 +/- 0.18) mmol/L (p < 0.01). No significant differences were observed between BCR-ABL1 negative MPN and control groups in plasma hydroperoxide and carbonyl protein rates (p > 0.05; p > 0.05). BCR-ABL1 negative myeloproferative neoplasms are associated with dysregulation of redox balance of oxidant /antioxidant leading to an oxidative stress status.